Lannett Files ANDA For US Advair Rival

Firm Reveals It Is Also In Negotiations Over Additional Respiratory Opportunities

Lannett has become the latest company to file an ANDA for a generic rival to GSK’s Advair Diskus in the US. Meanwhile, the company has revealed that it is also exploring further respiratory opportunities.

Lungs
Lannett is exploring further respiratory opportunities after filing for generic Advair • Source: Shutterstock

Lannett has confirmed filing of an abbreviated new drug application for a generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) in the US, becoming the latest company to formally pursue a rival to the respiratory blockbuster.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

More from Products